Login / Register Order My Items
Contact Us
800.227.0627
Contact Us Quote Order Login / Register

Oligonucleotide Delivery Modifiers and siRNA Conjugates

Lipids, sterols, fatty acids, vitamins, endosomal escape motifs, and CPP peptide conjugates — synthesized and conjugated in-house.

Lipid, sterol, vitamin, and CPP delivery modifiers for oligonucleotide conjugation—synthesized, conjugated, purified, and QC-validated in-house.

Request a Quote Browse modifier categories
Talk to a chemist Request a quote
Overview Catalog Mechanisms Design guidance Common modifications Advantages & future Platforms Related Services FAQ Reading Contact

Overview

Delivery modifiers are molecular modules covalently attached to therapeutic and research oligonucleotides—siRNA, miRNA, ASO, SSO, and PMO (including peptide–PMO)—to improve cellular uptake, biodistribution, and intracellular trafficking. Compared with larger carriers (e.g., LNPs, polymers, or complex formulations), oligonucleotide conjugates provide a defined 1:1 architecture, simpler analytics, and more predictable manufacturability, while enabling modular tuning of tissue uptake and endosomal escape.34

These delivery modifiers are widely used in modern RNA therapeutics including siRNA conjugates, ASO conjugates, GalNAc-siRNA constructs for liver targeting, and other oligonucleotide conjugation platforms.

What it is

Oligonucleotide – linker/spacer – delivery modifier (lipid/sterol/vitamin/CPP).

Where it’s used

siRNA, ASO, miRNA, DNA/RNA probes, and other oligonucleotide formats where cellular delivery is limiting.

What we provide

In-house synthesis, conjugation, purification (HPLC/UPLC), and construct-appropriate QC.

siRNA Conjugates SSO Conjugates ASO Conjugates GalNAc-siRNA PMO Conjugates CPP-oligo Conjugates
CPP peptides: CPP–oligo constructs are often used for delivery enhancement across modalities (including SSO and PMO). We synthesize peptides and oligos and perform conjugation, purification, and QC in-house.5
Supported modalities
siRNA • miRNA • ASO • SSO • PMO • Peptide–PMO • Tri‑GalNAc
Common attachment sites
5′ / 3′ termini • Strand-selective for siRNA • Program-dependent internal installs
Core outputs
Defined conjugates • Purified constructs • QC package (HPLC/UPLC ± LC‑MS/CE)

Delivery modifier catalog

Categories below are collapsible and include representative examples (common and uncommon). If you don’t see your specific modifier, share the structure or catalog number—our team can synthesize the modifier, design an appropriate linker or spacer, and perform oligonucleotide conjugation in-house.

Hydrophobic motifs that increase membrane affinity and tune biodistribution.

Modifier Primary role Design notes
Cholesterol Membrane affinity; uptake/PK tuning; widely used for siRNA Typically stable linker; spacer can improve solubility/purification
Cholesteryl hemisuccinate / cholesteryl carbonate Cholesterol variants with different coupling handles Useful for amide/carbonate chemistries
Fatty acids (C12–C22: lauric, myristic, palmitic, stearic, oleic) Hydrophobic anchor; albumin binding; biodistribution tuning Chain length impacts hydrophobicity and chromatography
Diacylglycerol / phospholipid anchors Membrane association; nanoparticle interactions Often needs spacer to reduce aggregation
Ceramide derivatives Membrane interaction; trafficking modulation Hydrophobic; method development may be needed
Squalene Hydrophobic self-assembly; improved uptake in some systems Often treated as delivery module; architecture-specific
Bile acids (cholic, deoxycholic, chenodeoxycholic) Amphiphilic uptake/PK tuning Useful for balancing hydrophobicity
Sterols (sitosterol, ergosterol) Sterol class delivery motifs Program-dependent performance

Vitamins can function as delivery modifiers (vitamin E), or as targeting/affinity modules (folate/biotin). Listed for coverage.

Modifier Primary role Design notes
α-Tocopherol (Vitamin E) Membrane interaction; delivery enhancement Often installed on siRNA sense strand; spacer tuning helpful
Retinoids (Vitamin A derivatives) Hydrophobic delivery motif; trafficking modulation Light/oxidation sensitivity for some retinoids
Vitamin D derivatives Hydrophobic scaffold; select delivery programs Program-dependent; evaluate stability/sterics
Folate (Vitamin B9) Receptor-targeting ligand (folate receptor) Primarily targeting; included for completeness
Biotin (Vitamin B7) Affinity handle (streptavidin capture) Primarily labeling; included for completeness

Program-specific delivery motifs used to tune hydrophobicity, serum binding, or membrane interaction.

Modifier Primary role Design notes
Alkyl chains / branched alkyls Hydrophobicity tuning; membrane association Spacer can reduce steric effects
Aromatic hydrophobes (pyrene, naphthalene motifs) Membrane interaction; probe delivery studies Often used in research constructs
Adamantane derivatives Hydrophobic cage; inclusion-complex workflows; uptake tuning Useful in modular supramolecular approaches
Steroidal amphiphiles Hydrophobic scaffold variants Program-specific optimization

Motifs used to support productive intracellular exposure (often via pH/charge switching or membrane interaction).

Modifier Primary role Design notes
Imidazole / histidine-mimetic motifs pH-buffering and trafficking modulation Often pendant groups or small motifs
Ionizable amines (tertiary amines) pH-dependent charge switching; endosomal support Balance charge to avoid nonspecific binding
Membrane-active amphiphiles Endosomal membrane interaction/disruption Evaluate compatibility and assay context
Disulfide-bearing delivery motifs Reductive trigger–responsive architectures Useful when intracellular release is required

non-hydrolyzable phospho pTyr analogs custom evaluation

CPPs are peptides (not small molecules), but are often grouped with delivery modifiers because the intent is delivery enhancement. We synthesize peptides and oligos and conjugate constructs in-house.

Modifier Primary role Design notes
TAT (HIV-1 Tat) peptide Classic CPP; uptake enhancement Peptide conjugate; grouped here by function
Penetratin CPP with uptake activity Often tested with spacer/linker variants
Poly-arginine (R8/R9/R11) Cationic CPP series; uptake modulation Charge density impacts binding/uptake
Transportan / TP10 Amphipathic CPP Program-dependent
Pep-1 / MPG CPP families used in nucleic acid delivery Often used for research delivery
RALA and amphipathic CPPs Endosomal escape–supporting CPP designs Sequence-specific performance
NLS-containing peptides Trafficking motifs used as delivery modules Application-dependent
Classification note: CPP constructs can also be presented under Oligonucleotide–Peptide Conjugates if you prefer strict taxonomy.

Handle choice is driven by modifier functional groups, stability requirements, and orthogonal assembly needs.

Modifier Primary role Design notes
Amino (5′/3′ NH2) Amide coupling to activated esters/acids Robust; widely used
Thiol (5′/3′ SH) Maleimide chemistry; disulfide formation Control oxidation; storage considerations
Azide SPAAC with DBCO/cyclooctynes Copper-free click preferred for therapeutic oligos
DBCO / cyclooctynes SPAAC partner for azides Bulky/hydrophobic; spacer helps
Tetrazine / TCO IEDDA ligation; fast modular assembly Stability/handling must be evaluated
Alkyne CuAAC (with copper) or alternative click strategies Use when appropriate; copper can affect nucleic acids

Mechanism-driven delivery design

Small-molecule oligonucleotide conjugates are often engineered around two complementary delivery mechanisms. (1) enhanced endosomal release and (2) enhanced membrane penetration via lipophilic motifs. 14

Endosomal escape is often the rate-limiting step for productive intracellular exposure. Small molecules and motifs can be selected to influence endosomal trafficking, pH-dependent membrane interaction, or compartmental release. 46

Strategy / motif How it helps Example use cases
Endosomal escape enhancers (small molecules) Compounds that increase oligo activity by improving escape from intracellular compartments; often optimized by SAR screens. SSO splice-switching enhancement; ASO/siRNA activity enhancement in cells and in vivo.
pH-responsive / ionizable motifs pH-dependent charge switching and membrane interaction can support endosomal release. ASO and siRNA delivery programs where endosomal escape limits potency.
CPP / cyclic CPP platforms CPPs promote uptake and can be designed to support endosomal escape and intracellular trafficking. Peptide–PMO/SSO constructs; intracellular splice correction and other functional readouts.
Practical approach: evaluate a matched set (placement × spacer × motif) and read out both uptake and function to avoid selecting modifiers that increase internalization without productive cytosolic exposure.

Lipophilic motifs (cholesterol, fatty acids, tocopherol, squalene, and related scaffolds) increase membrane association and serum protein binding, which can improve tissue distribution and cellular entry. 27

Lipophilic modifier Primary delivery effect Research & therapeutic examples
Cholesterol Membrane affinity; uptake/PK tuning; widely used as a benchmark lipophilic conjugate. Cholesterol–siRNA/ASO research constructs; tissue distribution tuning.
Fatty acids (palmitic, stearic, oleic) Albumin binding and hydrophobic anchoring; can increase exposure in multiple tissues. Palmitic acid–ASO distribution/activity studies; PK/PD tuning.
Vitamin E (α-tocopherol) Hydrophobic delivery motif; can improve uptake in some formats. Tocopherol–siRNA/ASO research programs.
Squalene Hydrophobic self-assembly and membrane association; architecture-dependent effects. Squalene–oligo constructs explored for enhanced delivery.

Design guidance

Placement strategy

For duplex siRNA, modifiers are commonly evaluated on the sense strand (often 3′) to preserve antisense RISC loading.

  • Screen 2 placements (5′ vs 3′ or strand choice)
  • Confirm activity with matched controls
Spacer & solubility

Hydrophobic modifiers often require spacer optimization to maintain solubility and enable clean purification.

  • PEG or alkyl spacers
  • Method development for hydrophobic conjugates
Analytics & QC

Select analytics that match the construct and modifier properties.

  • HPLC/UPLC purity and conversion
  • LC-MS when compatible
  • Orthogonal confirmation (UV/Vis, gel/CE)
Fast decision set: 2 placements × 2 spacer lengths × 1–2 modifiers provides a rapid decision signal for uptake and activity.

Common oligonucleotide modifications used in delivery systems

Delivery performance is a combined outcome of the delivery modifier and the oligonucleotide chemistry. These common modifications are frequently used alongside delivery conjugation to improve stability, potency, and in vivo exposure. 83

Modification class Examples Why it’s used
2′ sugar modifications 2′-O-Me, 2′-F, 2′-MOE, LNA/cEt (program-dependent) Increase nuclease resistance and binding affinity; tune potency and tolerability.
Backbone modifications Phosphorothioate (PS), mixed PS/PO patterns Improve stability and protein binding; can influence distribution and trafficking.
Base modifications 5-methyl-C and related base edits (as applicable) Tune duplex stability, immunostimulation risk, and activity.
Termini & capping 5′ caps, inverted bases, terminal stabilization motifs Reduce exonuclease susceptibility and improve in vivo durability.
Modality scaffolds PMO (morpholino), peptide–PMO constructs, other neutral scaffolds (project-dependent) Used when charge-neutral scaffolds or sterics are required; often paired with CPP delivery.
Tip: When comparing delivery modifiers, keep the oligo chemistry constant (same PS pattern and 2′ mix) to isolate the effect of the delivery module.

Why conjugates vs larger carriers — and where the field is going

Advantages over larger carriers
  • Defined architecture: a controlled composition (often 1:1) enables clearer structure–activity relationships.
  • Simpler CMC & analytics: fewer formulation variables than complex nanoparticles or polymers.
  • Modular tuning: swap ligand/spacer/placement without re-optimizing an entire formulation.
  • Scalable conjugation workflows: amenable to standardized synthesis, purification, and QC pipelines.

Carrier platforms remain valuable for some tissues and payload needs; conjugates are often preferred when a defined construct and predictable manufacturing are priorities.3

Future direction
  • Beyond liver: new small-molecule ligands and multivalency for extrahepatic targeting.
  • Endosomal escape enhancers: small-molecule EEEs and trafficking modifiers to increase productive cytosolic exposure.
  • Multi-functional conjugates: combined targeting + delivery + controlled release (cleavable linkers).
  • Modality expansion: optimized conjugates for miRNA, SSO, PMO, and peptide–PMO formats.

Active research focuses on improving endosomal escape and expanding tissue specificity for conjugate delivery.46

FAQ

What are delivery modifiers in oligonucleotide therapeutics?

Delivery modifiers are non-drug functional modules covalently attached to therapeutic or research oligonucleotides (siRNA, miRNA, ASO, SSO, PMO) to improve cellular uptake, biodistribution, membrane interaction, and intracellular trafficking. They enhance delivery performance but do not provide direct pharmacological activity.

Are cell-penetrating peptides (CPPs) considered delivery modifiers?

Yes. CPPs are peptides (not small molecules), but they are widely grouped under delivery modifiers because they enhance cellular uptake and intracellular trafficking. CPP–oligo conjugates are common for splice-switching oligos (SSO), PMO, and peptide–PMO programs.

Where are delivery modifiers typically installed on siRNA?

For duplex siRNA, delivery modifiers are commonly evaluated on the sense strand, often at the 3′ terminus, to help preserve antisense strand loading into RISC. Optimal placement is program-dependent and is usually confirmed with a small matched design set.

What are the most common small-molecule delivery modifiers for oligonucleotides?

Common motifs include cholesterol, fatty acids (palmitic/stearic/oleic), vitamin E (α‑tocopherol), squalene, sterol derivatives, bile acids, and amphiphilic lipid anchors. Selection depends on desired PK/PD, tissue distribution, and purification behavior.

Do delivery modifiers require cleavable linkers?

Not necessarily. Many delivery modifiers use stable linkers/spacers because their function is delivery enhancement. Cleavable linkers are evaluated when release is required for activity, when the modifier interferes with function unless removed intracellularly, or when controlled release improves signal-to-noise.

What advantages do conjugates have over larger carriers (LNPs/polymers)?

Conjugates typically provide a defined 1:1 architecture, simpler analytics and CMC, fewer formulation variables, and modular optimization by swapping ligand/spacer/placement. Carriers can still be preferred for certain tissues or payload needs, but conjugates are attractive when a defined construct and predictable manufacturing are priorities.

How do delivery modifiers influence endosomal escape?

Some modifiers increase internalization without improving productive cytosolic exposure. Endosomal escape is improved by motifs that affect trafficking, pH-dependent membrane interaction, or compartmental release (including select small-molecule escape enhancers and CPP designs). Functional assays are recommended alongside uptake measurements to confirm productive delivery.

How does spacer length affect delivery performance?

Spacer length and chemistry (PEG vs alkyl) can reduce steric interference, improve solubility, and change how the modifier presents to membranes or receptors. Spacer tuning often improves purification behavior for hydrophobic motifs and can materially affect activity.

Which oligonucleotide modalities can be conjugated with delivery modifiers?

Delivery modifiers can be attached to siRNA, miRNA, ASO, SSO, PMO (including peptide–PMO), and research probes. We support terminal and (program-dependent) internal attachment strategies with in-house synthesis, conjugation, purification, and QC.

What analytical methods confirm delivery modifier conjugation?

Typical QC includes HPLC/UPLC for purity and conversion, LC‑MS when compatible, and orthogonal confirmation such as UV/Vis ratios, gel electrophoresis, or capillary electrophoresis depending on construct and modifier.

What is the difference between lipid-conjugated siRNA and tri-GalNAc siRNA?

Lipid conjugates primarily increase membrane affinity and serum protein binding to tune biodistribution, whereas tri-GalNAc is a receptor-targeting ligand (ASGPR) designed for efficient hepatocyte uptake. The best choice depends on target tissue (liver vs extrahepatic), desired PK profile, and whether receptor-mediated uptake is required.

Which delivery modifiers are used for extrahepatic delivery?

Extrahepatic delivery is an active area of development. Programs often evaluate lipophilic motifs (fatty acids, sterols), trafficking/escape motifs, and CPP platforms, along with spacer and placement tuning. Because performance is tissue- and cell-type–dependent, a matched design set is typically used to identify the best modifier for a given target.

How does hydrophobicity affect oligonucleotide biodistribution and potency?

Increasing hydrophobicity can raise serum protein binding and membrane association, which may improve tissue exposure but can also change clearance and purification behavior. Hydrophobicity is usually tuned by modifier choice (cholesterol vs fatty acid vs tocopherol) and spacer length to balance uptake, distribution, and functional activity.

Why are cholesterol–siRNA conjugates widely used in research?

Cholesterol is a well-characterized lipophilic benchmark that reliably increases membrane interaction and changes biodistribution, making it useful for comparing architectures and placement strategies. Many labs use cholesterol conjugates as a reference point when screening new delivery modifiers or endosomal escape motifs.

More FAQ'sAll FAQ's

Contact & quote request

For the fastest review, share: oligo modality/sequence (and strand info for siRNA), the delivery modifier (structure or catalog number), intended attachment site (5′/3′/internal), and preferred handle chemistry (NH2, SH, azide/DBCO, tetrazine/TCO). For CPP constructs, include peptide sequence and desired linkage.

Information checklist
  • Oligo format: siRNA / ASO / DNA / RNA / aptamer / PNA / PMO
  • Modifier class: lipid/sterol, fatty acid, vitamin, endosomal motif, CPP peptide
  • Attachment site: 5′ / 3′ / internal (or strand for siRNA)
  • Spacer preference: PEG / alkyl / cleavable (if needed)
Fastest path
Request a quote Browse catalog

Recommended Reading

  1. Alfa Chemistry. Small molecule conjugate-based delivery systems (overview of endosomal release vs lipophilic conjugates).
  2. Pharmaceutics review. Delivery of Oligonucleotides: Efficiency with Lipid Conjugation and Other Delivery Enhancers.
  3. Nature Reviews Drug Discovery. Advances in oligonucleotide drug delivery.
  4. Trends in Biotechnology review. Strategies and mechanisms for endosomal escape of therapeutic nucleic acids.
  5. Molecular Therapy – Nucleic Acids. Endosomal escape vehicle platform enhances delivery of splice-switching oligonucleotides.
  6. Nucleic Acids Research. Structure–activity relationships of oligonucleotide enhancing compounds.
  7. Nucleic Acids Research. NAR virtual issue: Cellular/Tissue Delivery (includes palmitic acid–ASO distribution study).
  8. Nucleic Acids Research review. Chemistry, structure and function of approved oligonucleotide therapeutics.
  9. GalNAc review. Delivery of oligonucleotides to the liver with GalNAc.
  10. RNA journal review (PDF). Endosomal escape of RNA therapeutics.

Note: citations above are summaries; use DOI links in your CMS if you want outbound linking. This page is written for technical buyers and researchers.

Why Choose Bio-Synthesis

Trusted by biotech leaders worldwide for over 45+ years of delivering high quality, fast and scalable synthetic biology solutions.

Greetings Researchers,

Please be advised that any information, guidelines, writeups, and oral/video/graphic content on our website are intended solely as general guidelines.
It is the researcher's sole responsibility to conduct thorough research on the designs of the products intended for their experiments before submitting
their designs to Biosynthesis for review of production feasibility.
Thank you for your understanding.

Quick Links